DTDavid Thein

David Thein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Thein has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long-Term Disease Progression in Adult Atopic Dermatitis: A 6-Year Observational Study of Severity and Treatment Patterns

    by Lea Krog Nymand, Mia-Louise Nielsen, David Thein, Simon Francis Thomsen, Jacob P. Thyssen, Alexander Egeberg

    Introduction: Atopic dermatitis (AD) is a chronic and heterogeneous skin condition, often with a fluctuating and unpredictable disease course, which can be influenced by treatment patterns and significantly impact patients’ disease burden and mental health. The aim of the study was to characterize disease trajectories stratified by severity and treatment modality, and investigate their association with patient-reported signs, symptoms, and mental health burden. Methods: Patients (≥18 years) with a dermatologist-verified diagnosis of AD were included using data from the Danish Skin Cohort and the Danish National Prescription Registry. Patients were categorized into four groups based on AD severity (mild vs. moderate-to-severe) and treatment modality (non-systemic vs. systemic). Disease trajectories were initially identified through graphical assessment of the four groups over time, and subsequently each patient was assigned to a disease trajectory using the longest common subsequence method resulting in six clusters. Results: From 2018 through 2024, 234 patients were followed prospectively. Severity and treatment data were recorded at five time points. The majority of patients had moderate-to-severe AD throughout the study period without receiving systemic treatment or achieving remission, but the proportion receiving systemic treatment increased from 17.1% in 2018 to 29.1% in 2024 irrespective of disease severity. The three clusters with consistent moderate-to-severe AD showed similar baseline itch, body surface area, and flare frequency despite different treatment modalities. Clusters having mild AD at some time points showed comparable baseline profiles despite their different trajectories. Conclusion: A considerable proportion of patients with moderate-to-severe AD were managed without systemic therapies and experienced substantial burden and mental health impact. These findings highlight the heterogeneity and persistence of AD, including fluctuating disease activity and variability in treatment patterns, which emphasize the importance of incorporating longitudinal disease patterns into clinical decision-making.

  • Open Access

    Machine-learning-based Phenomapping of Patients with Keratinocyte Carcinoma: Data-driven Subgrouping by Disease Burden, Comorbidities and Socioeconomic Status

    by Johan Sieborg, Emily Wenande, Mia-Louise Nielsen, Mads Nielsen, David Thein, Merete Haedersdal

    Keratinocyte carcinoma (KC) places a considerable and growing burden on healthcare systems. Given the KC population’s heterogeneity, tailored clinical pathways are needed to accommodate diverse management needs. This study applied machine learning (ML)-based phenomapping to identify distinct real-world subgroups within a national KC population using demographic and medical history variables. The study included KC patients treated in publicly-funded, office-based dermatology practices and registered in the Danish Skin Cancer Registry (2014–2022). In 106,490 KC patients, 7 ML-derived clusters were identified. One cluster (22.2%; n=23,590) consisted primarily of young, well educated high-income medically noncomplex females presenting with low-risk basal cell carcinomas (BCCs). Four clusters (55.2%; n=58,736) comprised patients with a greater dermatological disease burden, characterized by facial BCCs, multiple BCCs, a greater proportion of squamous cell carcinomas (SCCs), a history of skin cancer or previous actinic keratosis-related treatment. The remaining 2 clusters (22.7%; n=24,164) comprised highly comorbid patients with a greater proportion of SCCs, a high number of KCs on the head and neck and high immunosuppressive drug exposure. ML-derived phenomapping of a national KC population identified distinct, clinically relevant KC subgroups, providing a basis for tailored clinical pathways with differentiated resource needs.

  • Preferences in atopic dermatitis: A systematic review

    by E. H. Pinborg, S. B. Laursen, D. Thein, I. Vittrup, C. Schlapbach, J. T. Maul, B. Dégboé, A. Egeberg, S. F. Thomsen, J. P. Thyssen, et al.

    Background: Numerous new treatments for atopic dermatitis (AD) have been approved in recent years, but it is unknown whether published patient, caregiver and healthcare provider preferences are biased by industry funding.Objectives: To investigate funding sources and their putative influence on patients, caregivers and healthcare providers' reported preferences with regard to different properties of therapies and treatment outcomes of AD.Methods: This descriptive systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses Guidelines. PubMed and EMBASE were searched. Studies were included if they reported data on AD patients', caregivers' and/or healthcare providers' preferences of therapy and/or treatment outcomes.Results: A total of 8346 studies were identified, and 42 were included for data synthesis (participants, 19,839; females, 62.2%). Nineteen and twenty‐three studies were pharma‐sponsored and non‐pharma‐sponsored, respectively. The pharma‐sponsored studies were of recent dates, had larger patient populations and included discrete choice experiments. Efficacy was of great importance to patients, caregivers and healthcare providers, and this finding was mainly driven by pharma‐sponsored studies. Moreover, patients were more willing to accept the risk of side effects or adverse events to achieve other treatment goals in pharma‐sponsored studies. Studies sponsored by companies producing Janus kinase inhibitors showed that patients preferred the least invasive administration route despite increased administration frequency. Studies evaluating preferred topical treatment attributes were often non‐pharma‐sponsored.Conclusions: The findings of this study indicate that preference research may be biased. Therefore, healthcare providers should be cautious when employing treatment needs and preferences research to support decision‐making.


  • Open Access

    Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study

    by Johan Sieborg, Julia-Tatjana Maul, Jashin J. Wu, Nikolai Nguyen Loft, Lone Skov, Lars Erik Bryld, Mads Kirchheiner Rasmussen, Tomas Norman Dam, Trine Bertelsen, Kawa Khaled Ajgeiy, et al.

    Biosimilars are designed to be analogous to the biologic originators. However, comprehensive comparisons between biosimilars are limited and lacking for patients with psoriasis. This study’s objective was to compare 1-year drug survival of the 2 adalimumab biosimilars, GP2017 with SB5, following a non-medical mandatory switch from the adalimumab originator. Based on the national clinical database DERMBIO, this nationwide cohort study included all patients with psoriasis treated with the adalimumab originator who underwent a non-medical mandatory switch to GP2017 or SB5. The study included 525 patients switching from adalimumab originator to 1 of 2 biosimilars: GP2017 (n=267 patients) or SB5 (n=258 patients). When comparing the drug survival of the biosimilars, the hazard ratio was 1.11 (95% confidence interval, 0.58–2.12) for SB5 with GP2017 as reference. In the sensitivity analysis investigating changes in PASI, no differences were found when comparing the GP2017 group and the SB5 group at 120 days of follow-up (1.9% vs 1.6% improved, 1.9% vs 2.0% worsened, and 43.1% vs 40.9% remained unchanged). When comparing GP2017 and SB5, no discernible differences were found in drug survival or effectiveness based on PASI. Determining drug survival and effectiveness could benefit patients and clinicians in treatment decisions.

  • Prevalence and Characteristics of Chronic Hand Eczema Among Adults in Denmark: A General Population‐Based Study

    by David Thein, Julia‐Tatjana Maul, Simone Ribero, Jonathan I. Silverberg, Alexander Egeberg, Jacob P. Thyssen

    Background: The epidemiology of chronic hand eczema (CHE) remains poorly examined. Objective: To investigate the prevalence of CHE in a general adult population and describe the characteristics of affected individuals. Methods: We investigated the prevalence and characteristics of CHE using a random sample from the general Danish population (The Danish Skin Cohort). CHE was defined as eczema on the hands or wrists during a minimum of three consecutive months or reoccurrence of hand eczema at least twice within 12 months. Results: Out of 11 166 adults, 1306 experienced hand eczema (HE) at some point in their lifetime. Within the last 12 months, 408 (3.7%) experienced HE, of which 332 (81.4%) reported CHE. The crude 1‐year period prevalence of CHE was 3.0% (95% confidence interval (CI), 2.7%–3.3%) while the standardised prevalence was 3.5% (95% CI, 3.3%–3.6%). Among adults with CHE, 70.8% were female, and the mean age was 48.0 years (standard deviation 16.6 years). Most individuals with CHE had two relapses ( n = 309, 93.1%), while n = 206, 61.1%, had HE for more than 3 months. Compared to HE, CHE was more likely diagnosed by a dermatologist and affect the fingers and back of the hand. Conclusion: The standardised prevalence was 3.5% (95% CI, 3.3%–3.6%) and 4.2% (95% CI, 4.0%–4.4%) for CHE and HE, respectively. We identified a large overlap between HE and CHE (81.4%) in adults from the general population, indicating that many individuals affected by eczema on the hands may experience a chronic course.


  • Open Access

    Impact of the pre‐biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study

    by David Thein, Mia‐Louise Nielsen, Julia‐Tatjana Maul, Simon Francis Thomsen, Jacob P. Thyssen, Alexander Egeberg

    Background: It is unknown whether the pre‐biologic treatment journey affects subsequent biologic drug survival.Objective: To examine the potential impact of a complex treatment journey on subsequent biologic drug survival in patients with psoriasis.Methods: The study utilized longitudinal data from Danish national registries and included all patients who, for the first time, initiated a biological treatment for psoriasis. Maximum follow‐up was 5 years and patients were included from 1 January 2010 to 30 June 2021. The study used three definitions of exposure to a complex treatment journey and the following conventional systemic treatments: acitretin, cyclosporine, dimethyl fumarate and methotrexate. The first definition was the cumulative number of treatment series. The second definition comprised the number of unique treatments. The third definition was time from the first conventional systemic treatment to biological therapy. Drug survival for the three definitions were illustrated using Kaplan–Meier curves and compared using log‐rank test. The sensitivity analysis largely confirmed these findings by grouping patients according to pharmacotherapy.Results: A total of 2496 patients were included in the study, with 1380 (55.3%) receiving adalimumab, 608 (24.4%) receiving ustekinumab, 271 (10.9%) receiving secukinumab, 166 (6.7%) receiving etanercept and 71 (2.8%) receiving infliximab. The mean age at initiation of biologics was 43.6 years (standard deviation (SD) 15.2 years), and most patients were male (62.9%). During the follow‐up of 5477 patient years, 1953 patients (78.2%) reached the main endpoint of discontinuation. Using a log‐rank test, the probability of remaining on treatment was unaffected by the three definitions of complexity of the treatment journey.Conclusion: None of the three exposures used to assess the complexity of the pre‐biologic treatment journey appeared to impact drug survival. As long as patients experience adequate disease control, these results suggest that conventional systemic treatment do not negatively impact the drug survival of subsequent biologics.


  • Open Access

    Psychosocial and mental impact of alopecia areata: Analysis of the Danish Skin Cohort

    by Maria Elise Ross Clemmesen, Susanne Thiesen Gren, Anne Grete Frøstrup, Simon Francis Thomsen, Alexander Egeberg, David Thein

    Importance: Alopecia areata (AA) carries a psychological burden for patients beyond hair loss. However, quality‐of‐life measurement tools such as EQ‐5D used in clinical trials may not adequately capture the burden of AA, the perceived stigmatization or the psychosocial impact of AA.Objective: To investigate the potential association between disease severity and the degree of social isolation, perceived stigmatization, anxiety and depression, alcohol consumption and work absenteeism using multiple PRO measures in patients with AA.Design, Setting and Participants: Using the Danish Skin Cohort, the study included adult patients diagnosed with AA. The study included multiple PRO measures, including Skindex‐16, EQ‐5D‐5L, Work Productivity and Activity Impairment (WPAI), Alcohol Use Disorders Identification Test‐Consumption (AUDIT‐C) and the Alopecia Areata Symptom Impact Scale (AASIS). The questionnaires were dispatched to the patients in January 2023. The severity of AA was determined based on scalp involvement using a modified Alopecia Areata Scale. Multiple multivariate linear regressions were conducted using Skindex‐16, AASIS and WPAI, while multivariate logistic regressions were applied to HADS, AUDIT‐C and EQ‐5D‐5L.Results: A total of 376 patients were included, of which 177 (47%) had severe disease, 41 (11%) had moderate disease, 94 (25%) had mild disease, and 64 (17%) were in remission. The median age of patients was 55 (IQR, 47–66 years) and most were female (70%). Skindex‐16 and AASIS were the only PRO measures able to distinguish between severity. For these scores, moderate and severe diseases, female sex, and involvement of eyebrows increased the score and negatively impacted patient quality of life.Conclusion and Relevance: The results indicate the importance of using the proper tool for the intended measurement of quality of life and that factors such as the severity of AA, as well as female sex and involvement of the eyebrows, may potentially increase the psychosocial burden of AA.


  • Prevalence of ichthyoses in Denmark: a nationwide registry-based study

    by David Thein, Julia-Tatjana Maul, Peter Schmid-Grendelmeier, Jacob P Thyssen, Alexander Egeberg

    The results demonstrate a prevalence of 1.6 per 10 000 for all types of ichthyoses, based on large Danish national patient registries, including all patients with relevant diagnoses alive on 31 December 2021. A study of this size and depth has not been completed before but may still underestimate the prevalence and potential burden of the diseases.


  • Open Access

    Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study

    by Ida Vittrup, David Thein, Simon Francis Thomsen, Alexander Egeberg, Jacob P. Thyssen

    The European Medicines Agency recently limited the use of oral Janus kinase inhibitors in certain patient populations, including those with atopic dermatitis. This cross-sectional study used the Danish national registers and Danish Skin Cohort to assess the prevalence of risk factors that potentially impact choice of treatment with oral Janus kinase inhibitors in adult patients with atopic dermatitis. From the Danish national registers and Danish Skin Cohort, 18,618 and 3,573 adults with atopic dermatitis, respectively, were identified. Half of the patients (49.5%) had, at some point, been registered to have at least 1 risk factor that could impact treatment with oral Janus kinase inhibitors. Non-modifiable risk factors recorded were cancer (5.6%), major adverse cardiovascular events (2.6%), venous thromboembolism (2.0%), smoking history (15.6%), and age ≥ 65 years (12.4%). Among patients ≥ 65 years of age, the mean (standard deviation) number of risk factors were 3 (1.4), and almost half of these patients had, at some point, been registered to have 1 or more non-modifiable risk factors in addition to their age. In conclusion, risk factors that may impact treatment with oral Janus kinase inhibitors were frequent in Danish adults with atopic dermatitis, especially among older individuals. Dermatologists need support and continuously updated long-term safety data when risk-evaluating patients with atopic dermatitis prior to initiation of advanced


  • Open Access

    Demographics, characteristics and medical treatment among adults with hand eczema in Denmark. A cross‐sectional validation and registry‐based study

    by Maria Oberländer Christensen, Yasemin Topal Yüksel, Ida Vittrup, Lea Krog Nymand, David Thein, Line Brok Nørreslet, Jakob Maarbjerg Toft‐Hansen, Anne Klose Janstrup, Claus Zachariae, Mette Sommerlund, et al.

    Background: The international classification of diseases, 10th revision (ICD‐10) includes several unvalidated diagnostic codes for hand eczema (HE). Knowledge is sparse on HE patient characteristics.Objectives: To validate selected HE ICD‐10 codes in the Danish National Patient Registry (DNPR) and describe disease characteristics, lifestyle factors and medication use in adult HE patients.Methods: Nineteen HE ICD‐10 codes were selected and validated based on patient charts. Five cohorts were constructed based on the diagnostic code, DL30.8H (HE unspecified), in the DNPR: (i) patients with DL30.8H code (n = 8386), (ii) patients with DL30.8H code, but without atopic dermatitis (AD) (n = 7406), (iii) sex‐ and age‐matched general population (n = 8386) without HE. Two additional cohorts nested in the DNPR included participants from the Danish Skin Cohort, (iv) patients with DL30.8H code but without AD (n = 1340) and (v) general population cohort (n = 9876).Results: ICD‐10 codes revealed positive predictive values ≥90% except irritant contact dermatitis (unspecified) (79.7%) and hyperkeratotic hand and foot eczema (84.1%). HE patients were most often women, middle‐aged or older, of Danish ethnicity, had an atopic medical history and were smokers. Topical corticosteroid prescriptions were almost doubled in HE cohorts compared to general populations.Conclusion: We validated several HE ICD‐10 codes and identified important HE patient characteristics.